Partnering is a core element of our corporate strategy. We are continuously evaluating promising opportunities for acquisition or partnership and try not to let structure get in the way of substance. We search for assets where our development and operational expertise can optimize programs that might benefit from a fresh approach. We typically look for assets that are de-risked by signals of efficacy and acceptable safety in patients. Within rare diseases we are agnostic to therapeutic area, but have recently succeeded in areas related to GI / Hepatology, diseases of structural malformations, metabolic disorders, and neurological disorders.

If you have an idea that might fit ArTara’s strategy, please let us know.